imipramine has been researched along with cyclopentane in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biddy, RL; Bidus, DR; Korol, B; Yaffe, GJ | 1 |
| Cooper, MM; Day, JS; Sethy, VH | 1 |
| Lippmann, W; Seethaler, K | 1 |
| Howley, A; Jacobs, NL; Liscum, L; Underwood, KW | 1 |
| Brański, P; Kłak, K; Pałucha, A; Pilc, A; Wierońska, JM | 1 |
| Adebesin, A; Adeoluwa, OA; Eduviere, AT; Umukoro, S | 1 |
| Adebesin, A; Ajayi, AM; Olonode, EO; Omorogbe, O; Umukoro, S | 1 |
8 other study(ies) available for imipramine and cyclopentane
| Article | Year |
|---|---|
A behavioral and autonomic nervous system study of chronic imipramine administration to conscious dogs.
Topics: Animals; Autonomic Nervous System; Behavior, Animal; Blood Pressure; Cyclopentanes; Dogs; Epinephrine; Female; Heart Rate; Imipramine; Male; Norepinephrine; Serotonin; Time Factors; Yohimbine | 1978 |
Dose-dependent down-regulation of beta-adrenergic receptors after chronic intravenous infusion of antidepressants.
Topics: Amitriptyline; Animals; Antidepressive Agents; Cerebral Cortex; Cyclopentanes; Desipramine; Dose-Response Relationship, Drug; Female; Imipramine; Infusions, Intravenous; Iprindole; Kinetics; Rats; Rats, Inbred Strains; Receptors, Adrenergic, beta; Reference Values; Zimeldine | 1988 |
[German pharmacopoeia, 7th edition. IX. Delivery].
Topics: Alcohols; Amino Alcohols; Barbiturates; Blood Group Antigens; Carbamazepine; Cyclopentanes; Dexamethasone; Digitoxin; Germany, East; Glyburide; Imipramine; Immune Sera; Indocyanine Green; Infusions, Parenteral; Mephentermine; Mydriatics; Nandrolone; Parasympatholytics; Pharmacopoeias as Topic; Phenylacetates; Piperidines; Propoxycaine; Propylamines; Smallpox Vaccine; Structure-Activity Relationship; Thyroxine; Triiodothyronine | 1973 |
Oral anti-ulcer activity of a synthetic prostaglandin analogue (9-oxoprostanoic acid: AY-22,469).
Topics: Administration, Oral; Animals; Carboxylic Acids; Cold Temperature; Cyclopentanes; Imipramine; Immobilization; Injections, Intraperitoneal; Ligation; Male; Peptic Ulcer; Prostaglandins; Pylorus; Rats; Reserpine; Stress, Physiological | 1973 |
Evidence for a cholesterol transport pathway from lysosomes to endoplasmic reticulum that is independent of the plasma membrane.
Topics: Amphotericin B; Androstenes; Animals; Biological Transport; Brefeldin A; Cell Membrane; CHO Cells; Cholesterol Esters; Cholesterol Oxidase; Cholesterol, LDL; Cricetinae; Cyclopentanes; Endoplasmic Reticulum; Enzyme Inhibitors; Imipramine; Lipoproteins, LDL; Lysosomes; Microscopy, Fluorescence; Oleic Acid; Sphingomyelin Phosphodiesterase; Sterol O-Acyltransferase | 1998 |
Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cerebral Cortex; Citalopram; Colforsin; Cyclic AMP; Cyclopentanes; Dose-Response Relationship, Drug; Gene Expression Regulation; Hippocampus; Imipramine; Male; Rats; Receptors, Metabotropic Glutamate; Tricarboxylic Acids | 2007 |
Methyl jasmonate attenuated lipopolysaccharide-induced depressive-like behaviour in mice.
Topics: Acetates; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Brain; Corticosterone; Cyclopentanes; Depression; Disease Models, Animal; Imipramine; Infusions, Parenteral; Jasminum; Lipopolysaccharides; Male; Mice; Oxidative Stress; Oxylipins; Plant Extracts; Tumor Necrosis Factor-alpha | 2017 |
Methyl Jasmonate Ameliorates Unpredictable Chronic Mild Stress-Induced Behavioral and Biochemical Alterations in Mouse Brain.
Topics: Acetates; Animals; Behavior, Animal; Brain; Corticosterone; Cyclopentanes; Disease Models, Animal; Glutathione; Imipramine; Male; Malondialdehyde; Mice; Oxylipins; Stress, Psychological; Superoxide Dismutase; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |